Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HKH40A

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

RTA 502

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
HKH40A downregulates GRP78/BiP expression in cancer cells
HKH40A, the 8-methoxy analog of WMC79, is a synthetic agent with promising in vitro and in vivo antitumor activity, especially… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Abstract 1231:In vitroanticancer activity of imidazo-acridinone (HKH40A) in panels of human patient-derived tumor xenografts (PDXs) and human leukemia and lymphoma cell lines
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA HKH40A is a synthetic, DNA-intercalating (Kosakowska… Expand
2009
2009
Involvement of ATM‐mediated Chk1/2 and JNK kinase signaling activation in HKH40A‐induced cell growth inhibition
HKH40A (RTA 502), or 5‐nitro‐2‐(3‐{4‐[3‐(8‐methoxy‐6‐oxo‐6H‐2,10b‐diaza‐aceanthrylen‐5‐ylamino)propyl]piperazin‐1‐yl}‐propyl)‐2… Expand
2008
2008
Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79
HKH40A (RTA 502), an optimized 8-methoxy analog of the unsymmetrical bifunctional antitumor agent WMC79, was found to be potently… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502).
Unsymmetrical bifunctional antitumor agent WMC79 was further optimized to generate compound 7b that not only inhibited the growth… Expand
2006
2006
288 POSTER Selective targeting of critical components of DNA replication by HKH40A (RTA 502)
2004
2004
549 HKH40A, potent agent agaist GI cancers, targets p53 or when that is mutated, Akt
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE